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Key Messages
1. Chronic steroid therapy causes 
disturbance in cell proliferation 
of the hippocampus and the 
subventricular zone. This may 
be the underlying cause of 
altered memory and cognitive 
function.
2. Co-administration of paroxetine 
(a class of antidepressants) 
during steroid therapy could 
counteract the destruction. 
Modification of the current 
steroid therapy regimen may be 
required.
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Introduction
Corticosteroid decreases neural cell production in the hippocampus,1 whereas 
antidepressants induce neurogenesis.2 The hippocampus is a brain region for 
memory formation. Decreased production of neurons in this region has a negative 
impact on cognitive function. We assessed the hypothesis that the neuro-damaging 
effect of high-dose corticosteroid on the hippocampus and subventricular zone 
(SVZ) could be reversed by administration of paroxetine—a selective serotonin 
reuptake inhibitor for treatment of depressive disorders. A rodent model was 
used to test the effect of paroxetine, corticosterone, and co-treatment of these two 
drugs on neurogenesis of the hippocampus and SVZ. In patients receiving steroid 
therapy, the neuroprotective effect of paroxetine suggests that administration 
of antidepressant could prevent deterioration of neuron production. This study 
aimed to investigate drug interactions of paroxetine, lithium, and corticosterone 
on the hippocampus and SVZ in terms of cell proliferation, dendritic morphology, 
neuronal survival, and molecular mechamisms, and whether selective serotonin 
reuptake inhibitor and lithium could exert protection against corticosterone-
induced neuron damage on the hippocampus and SVZ.
Methods
This study was conducted from January 2005 to December 2006. Six groups 
of rats (n=4-5 for each group) were divided into: (1) 14 days of corticosterone 
injections (40 mg/kg, subcutaneously), (2) 14 days of paroxetine injections (10 
mg/kg, intraperitoneally), (3) 14 days of both corticosterone and paroxetine 
injections (same dosage as above), and (4) 14 days of vehicle injections. 
 To study the effect of lithium and corticosterone on dendritic morphology, the 
rats were divided into: (1) 14 days of lithium treatment (85 μg/kg, n=6), and (2) 
14 days of lithium and corticosterone treatment (same dosage as above, n=6). 
 Proliferative cells in the hippocampus and SVZ were labelled by 
bromodeoxyuridine (BrdU) injection (50 mg/kg) during the final 3 days of 
treatment. After 14 days of treatment, rats were sacrificed by decapitation, and 
their brains were processed for BrdU immunohistochemistry or Golgi staining. 
During the treatment period, another set of experimental rats was sacrificed and 
their hippocampi were dissected for quantitative polymerase chain reaction. 
 For the differentiation and neurogenesis study, the rats were divided into 4 
groups as described above, with each group containing 6 rats. The rats were 
allowed to survive for 3 weeks after completion of the 14 days’ treatment. The 
total number of rats used was 135.
BrdU immunohistochemistry 
Frozen slices of the hippocampus and SVZ were slide-mounted and boiled in 
citric acid (pH=6.0) for 10 mins, followed by PBS rinses. The brain sections 
were incubated in 1M HCI (37ºC, 30 mins) and then boric acid buffer (pH=8.5, 
10 mins). After blocking with 5% normal goat serum in 0.01% Triton X-100, 
sections were incubated overnight with anti-mouse BrdU (1:400, Roche) at 4ºC. 
Sections were then incubated for 1 hr with secondary antibody (biotinylated goat 
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anti-mouse; Vector Laboratories), followed by amplification 
with an avidin-biotin complex (Vector Laboratories). 
Cells were then visualised with diaminobenzidine. For the 
neurogenesis study, co-immunostaining with rat anti-BrdU 
antibody (1:1000, abcam) and mouse anti-NeuN (1:1000, 
Chemicon) were used as primary antibody. Secondary 
antibodies were goat anti-mouse and rat (Alexor fluor 488 
and 563, Molecular Probes). The chemical supplier was 
Sigma-Aldrich unless otherwise indicated. 
Golgi staining
Golgi staining was carried out using the FD Rapid 
GolgiStain Kit according to the manufacturer’s protocol. In 
brief, the brains of the treated rats were immersed in the 
impregnation solution for 2 weeks, after which the tissue 
was cut into 50-micron-thick sections and stained. 
Quantitative polymerase chain reaction 
Hippocampi of the rats in the three treatment groups 
(corticosterone, paroxetine, and co-treatment) were taken 
out at different time points: 4 hours, 2 days, 4 days, 7 days, 
and 14 days after treatment. Hippocampal tissues were 
dissected and stored at -70ºC until use. Hippocampal RNA 
was extracted with Trizol reagent (Invitrogen) according 
to the manufacturer’s protocol. Gene expression of brain-
derived neurotrophic factor (BDNF) and cAMP response 
element-binding protein (CREB) among different groups 
of rats at different time points were measured by the 
iCycler iQ™ Multi-Color RT-PCR System. The primer 
sequences and probe for amplification of BDNF were: 
5’-CTGACACTTTTGAGCACGTGATC-3’ (forward), 
5’-CGTTGGGCCGAACCTTCT-3’ (reverse), and 
5’-CATCCAGCAGCTCTTC-3’ (probe). The primer 
sequences of GAPDH (as internal controls) were: 
5’-CAGAACATCATCCCTGCATCCA-3’ (forward), 
5’-CCGTTCAGCTCTGGGATGAC-3’ (reverse), and 5’- 
CTTGCCCACAGCCTTG-3’ (probe).
Data quantification and statistical analysis
BrdU-positive cells on every 12th unilateral section 
through the whole dentate gyrus were counted at ×1000 
magnification, with the aid of the Stereo Investigator 
software. BrdU-positive cells in the dentate gyrus were 
counted from 2400 to 3600 μm posterior to Bregma. In 
SVZ, BrdU cells were counted from 1800 to 0 μm anterior 
to Bregma. The number of BrdU-labelled cells per dentate 
gyrus was then multiplied by 24 to estimate the total 
number of BrdU-positive cells through the dentate gyrus. 
The number of BrdU-positive cells in the hippocampal 
subgranular zone in each group was defined as a percentage 
of control (vehicle). For SVZ sections, the cell number was 
expressed as the number of cells per section. 
Brain-derived neurotrophic factor enzyme-linked 
immunosorbent assay
BDNF enzyme-linked immunosorbent assay (ELISA) 
kits (Chemicon) were used to assess hippocampal BDNF 
protein level after 14 days of treatment. Protein extracts 
were prepared from snap-frozen rat hippocampi. For each 
rat, 50 μg of protein extract was used for assay. ELISA was 
carried out according to the manufacturer’s protocol.
Results
Adrenal gland atrophy caused by subchronic 
corticosterone treatment
After 14 days of treatment, the adrenal glands were dissected 
and weighed. Respectively in the control, corticosterone, 
co-treatment, and paroxetine groups, the mean adrenal 
weights (in g) were 27.63±4.85, 6.20±2.78, 10.633±1.46, 
and 45.47±14.15. Adrenal weights of the rats in the 
corticosterone and co-treatment groups decreased, which 
indicated hypercortisolaemia induction and chemically 
induced lesions. This confirmed that the rats were subjected 
to chronic exposure of high-dose corticosterone during the 
treatment period. 
Hippocampal neurogenesis after corticosterone and 
paroxetine treatment
In the cell proliferation assay, the number of proliferating 
cells was identified by immunohistochemical detection of 
BrdU within the nuclei of actively dividing cells. The BrdU-
positive nuclei were clustered in the subgranular layer and 
hilus and exhibited irregular shape. In the experiment, only 
subgranular layer cells were counted. Compared to the 
controls, corticosterone significantly decreased the number 
of BrdU-labelled cells in the dentate gyrus (2470.00±31.56 
vs 1677.38±146.97, P<0.05). Chronic treatment with 
paroxetine significantly increased BrdU-labelled cells 
(13255.71±83.98, P<0.001) in the subgranular and granule 
cell layer, compared to the corticosterone or vehicle-alone 
group. The number of BrdU-positive cells in the co-treatment 
group (2204.48±90.40) was not significantly different from 
the vehicle-treated controls. For neuronal differentiation, no 
difference in the percentage of BrdU-labelled cells showing 
NeuN expression was noted among the four groups. 
This indicated that subchronic corticosterone treatment 
decreased hippocampal neurogenesis, whereas co-treatment 
with paroxetine increased the effect to a level similar to 
controls. In short, antidepressant therapy may be effective 
in preventing neurological damage caused by subchronic or 
chronic steroid therapy.
Morphological analysis by Golgi staining
Brain tissues were subjected to Golgi staining to study 
morphological changes (dendritic trees and spines) of 
hippocampal neurons after treatment. In the corticosterone, 
lithium, and co-treatment groups, at least five neurons were 
traced using the Neurolucida software, and the data were 
analysed using the NeuroExplorer software. The number of 
neuronal nodes (ie the number of dendritic tree branches) in 
the corticosterone group was significantly lower than in the 
lithium and co-treatment groups (13.5±4.36 vs 32±6.00 vs 
33.63±12.00, P<0.05). The mean dendritic length of each 
neuron (in μm) in the corticosterone group was significantly 
smaller than in the other two groups (410.0±49.7 vs 
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1762.6±182.4 vs 2068.6±782.9, P<0.05). This indicated 
that corticosterone decreased dendritic length and the 
number of dendrite branches, whereas corticosterone plus 
lithium could reverse the changes. 
Effect of drug treatment on hippocampal cell death
Cell death in the hippocampus was assessed by Nissl 
staining. No cells with pyknotic appearance (ie undergoing 
apoptotic cell death) were detected with cresyl-violet 
staining in any treatment group. This indicated that 
subchronic corticosteroid treatment was unlikely to cause 
neurological damage by increasing hippocampal cell death, 
and that antidepressants may not exert their therapeutic 
effect by protecting neurons from apoptosis. 
Quantification of change of brain-derived 
neurotrophic factor and cAMP response to element-
binding protein after drug treatments
The quantitative polymerase chain reaction was used for 
detecting alteration of BDNF and CREB levels in the 
hippocampus. In contrast to expectation, BDNF gene 
expression levels in all treatment groups decreased but not 
significantly across the treatment period when compared to 
day 0. 
Brain-derived neurotrophic factor protein expression 
by enzyme-linked immunosorbent assay
The BDNF level in the hippocampus decreased significantly 
in corticosterone-treated rats than in vehicle-treated rats 
(66.88±4.22 vs 90.2±6.63 ng/mL, P<0.05, ANOVA with 
LSD post-hoc test). Co-treatment with corticosterone and 
paroxetine (87.73±6.65 ng/mL, P>0.05) prevented the effect 
of decreased BDNF expression, compared to controls. No 
significant difference was noted between the vehicle group 
and paroxetine-treated group (90.2±6.63 vs 99.07±8.42 ng/
mL, P>0.05).
Effect of corticosteroid and paroxetine on 
subventricular zone neurogenesis
Similar to the findings for hippocampus cell proliferation, 
corticosterone treatment significantly reduced the number 
of BrdU-positive cells in SVZ, whereas paroxetine 
treatment significantly increased the number. Respectively 
in the control, corticosterone, paroxetine, and co-treatment 
groups, the numbers of BrdU-positive cells in SVZ were 
324.0±33.3, 264.1±28.1, 434.9±36.2, and 330.9±23.2 cells/
section (P<0.05 for control vs corticosterone and control vs 
paroxetine). 
Discussion 
Using the cell birth-dating technique (BrdU labelling), the 
numbers of proliferative cells in the hippocampus and SVZ 
were noted to increase with paroxetine treatment. However, 
no pyknotic cells were observed in the hippocampus in any 
of the treatment groups, indicating that the drugs had no 
significant effect on cell survival in our treatment paradigm. 
The neurogenesis-promoting effect of antidepressants may 
be due to their influence on the serotonergic system and 
thus the serotonergic pathways.3 Lithium could reverse the 
adverse effect of corticosterone on the dendritic complexity 
of the hippocampal CA3 region. Administration of lithium 
during steroid therapy may prevent the undesirable effect 
of high-dose steroid, but further investigation is needed to 
determine its behavioural consequence. The intracellular 
mechanisms responsible for the neurogenic effect remain 
unclear, but are likely to involve more than one intracellular 
pathway. Previous studies have suggested a major role of 
the cAMP-CREB cascade4 in the process, and that BDNF 
may be essential for neurogenesis. In our study, the ELISA 
data showed increased levels of BDNF in paroxetine-
treated rats. 
Conclusions
Paroxetine, a potent selective serotonin reuptake inhibitor, 
could reverse the adverse effect of corticosteroid on 
hippocampal and SVZ neurons. Paroxetine could induce 
cell proliferation in both neurogenic regions and restore the 
number of hippocampal proliferative cells in corticosteroid-
treated rats. Dendritic morphology study revealed that 
lithium may be beneficial for dendritic arborisation under 
the stress condition created by corticosterone treatment. 
Future studies may investigate the behavioural consequence 
of altered neurogenesis and dendritic morphology. Also, the 
molecular interaction between BDNF and CREB is worth 
studying. Understanding the molecular mechanisms in 
the neuroprotection of antidepressants may help patients 
undergoing steroid therapy in preventing cognitive 
deterioration. 
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